Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2011 June;66(3) > Minerva Chirurgica 2011 June;66(3):235-44

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CHIRURGICA

A Journal on Surgery


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,877


eTOC

 

  LUNG CANCER


Minerva Chirurgica 2011 June;66(3):235-44

language: English

Novel therapies in non-small cell lung cancer

Zaba O., Grohe C., Merk J.

ELK Berlin Chest Hospital, Berlin, Germany


PDF  


Over the last years, several new systemic cancer therapy strategies have been introduced to turn the growing insights of molecular aberrations involved in the development and progression of lung cancer into better treatment options fort the patients. This review presents some of the most importent biological targets and biomarkers relevant in the treatment of non–small cell lung cancer. Especially EGFR mutations, anti-angiogenesis, multi kinase inhibition, vascular disrupting agents, vaccines, m-TOR inhibitors, TRAIL inhibition and several biomarkers are highlighted including current study results.

top of page

Publication History

Cite this article as

Corresponding author e-mail

okau.zaba@elk-berlin.de.